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METHODS: Data for the cost-effectiveness analyses were
obtained from a case control study and two randomized
controlled trials comparing the surgical outcomes related
to temperature control using the Arctic Sun versus the
current surgical warming methods. The incremental cost-
effectiveness per hypothermia case avoided was calcu-
lated by measuring the extra costs to the hospital for
achieving an extra unit of effectiveness by using the Arctic
Sun.
RESULTS: Using the deﬁnition of hypothermia as a 
temperature less than 36°C, there were three cases (5%)
of post-operative hypothermia out of 58 for patients
warmed using the Arctic Sun method. Using the standard
of care, 23 out of 48 patients (48%) were hypothermic.
The treatment costs for preventing post-operative
hypothermia includes $60 in variable costs for the stan-
dard of care. Costs for using the Arctic Sun for prevent-
ing post-operative hypothermia included $350 in variable
costs and $9.85 in allocated annual ﬁxed costs (total
treatment cost—$359.85 per patient). Subtracting the rel-
ative cost to treat 100 patients using the standard of care
($6,000) from the relative cost of warming 100 patients
using the Arctic Sun ($35,985) yielded an incremental
cost effectiveness of $697.33 per post-operative hypother-
mia case avoided by using the Arctic Sun. 
CONCLUSION: Use of the Arctic SunTM is both effective
and cost-effective in preventing post-operative hypother-
mia during OPCAB procedures.
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Approximately 1.5 million individuals experience a
myocardial infarction (MI) each year in the United States.
Of these, 20% develop major depression (MDD) and are
at increased risk of re-infarction, overall morbidity and
mortality.
OBJECTIVE: The objective of this study was to compare
the health care costs and resource utilization for patients
diagnosed with MI + MDD with patients with MI only,
MDD only and a control group having neither condition. 
METHODS: Claims data for all patients at least 40 years
of age from a large HMO in the Southeast US were ana-
lyzed retrospectively. Patients were selected for study if
they had an incident event of MI, MDD, or MI+MDD
during a one-year recruitment period. Age and sex
matched patients having neither MI nor MDD during the
recruitment period served as the control group. Patients
were followed for two years from their dates of recruit-
ment. Patients were included in the MI+MDD group only
if they had at least six months of data for analysis. Only
patients with drug charges were included for ﬁnal 
evaluation.
RESULTS: Compared with $6,877 for patients in the
control group (n = 436), mean total costs were statisti-
cally different for each group, including $13,982 for
MDD patients (n = 296), $35,589 for MI patients (n =
98), and $57,835 for MI+MDD patients (n = 53). Signif-
icant differences between the groups were found for the
number of hospitalizations, length of hospital stay, out-
patient visits, types of prescribed medication, and number
of ﬁlled prescriptions. Other signiﬁcant differences be-
tween groups included their need for therapeutic drug
assays, particularly digoxin, and cardiovascular labora-
tory procedures, particularly the use of devices to monitor
for arrhythmia. 
CONCLUSION: The cost of illness and resource utiliza-
tion for patients who had MI+MDD are much greater
than patients having MI or MDD alone. Early recogni-
tion of patients with MI+MDD is warranted.
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Validity and clinical relevance of the quality of life (QL)
measures developed in Western civilization societies may
quite differ from those in countries experiencing socioe-
conomic hardships.
OBJECTIVES: We aimed to validate the set of QL ques-
tionnaires in essential hypertensives (EH) from Belarusian
population. 
METHODS: Internationally recognized, self-
administered, culturally non-speciﬁc, and professionally
translated into Russian questionnaires were used: the
General Well-Being Adjustment Scale (GWBAS), Duke
Health Proﬁle (DHP), Giessen Somatic Complaints Ques-
tionnaire (GSCQ). The QL assessment was carried out in
212 EH without concomitant diseases (100 males; mean
age 48.5 ± 12.3 years; BMI 30.3 ± 13.3kg/m2; SBP 168.4
± 26.6mmHg, DBP 105.4 ± 13.3mmHg) and in 57 
age-, gender- and BMI-matched healthy subjects.
RESULTS: Cronbach’s coefﬁcient alpha more then 0.7
was determined for GWBAS subscales (range 0.67–0.84;
mean 0.77) excepting “self-control”, for GSCQ (range
0.54–0.86; mean 0.74) excepting “gastric complains”,
but not for DHP (range 0.47–0.68; mean 0.57). Correla-
tion matrix revealed signiﬁcant and the highest Spearmen
correlation coefﬁcients of GWBAS subscales scores with
corresponding DHP and GSCQ subscales scores, except-
ing GWBAS subscale “vitality”. The total well-being
